Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAME: Focal Mass Drug Administration for Vivax Malaria Elimination in Peru
NCT05690841Phase 3Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2024
- Primary completion
- May 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tafenoquine, chloroquine, primaquine in Plasmodium vivax malaria, sponsored by University of California, San Francisco. Started Oct 2024; status: recruiting.
02
Drugs
tafenoquinechloroquineprimaquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT05690841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690841.